| Cat.No. | Name | Information |
|---|---|---|
| M1768 | Rapamycin | Rapamycin (Sirolimus,Rapamune)is an inhibitor of mTOR.The mammalian target of rapamycin (mTOR) is a kinase responsible for mitogen-induced cell proliferation/survival signaling. |
| M3722 | Temsirolimus | Temsirolimus (WAY-130779, CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM. |
| M1666 | AZD8055 | AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM. |
| M2151 | INK128 (Sapanisertib) | INK128 (Sapanisertib; MLN0128) is a potent and selective dual TORC1/2 inhibitor with IC50 of 1 nM. |
| M1709 | Everolimus | Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM. |
| M9050 | MHY1485 | MHY1485 is an mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes. |
| M2276 | Torin 1 | Torin 1 is a potent and selective inhibitor of mTOR with IC50 of 2 and 10 nM for mTORC1 and mTORC2, respectively. |
| M43384 | mTOR inhibitor-12 | mTOR inhibitor-12 is a selective brain penetrant mTOR inhibitor without genotoxicity risk. |
| M43383 | Royleanone | Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis. |
| M39838 | Zederone | Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells. |
| M29786 | MHY-1685 | MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. |
| M29584 | RMC-6272 | RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. |
| M29096 | eCF309 | eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC50 = 10-15 nM, both in vitro and in cells). |
| M29030 | PQR626 | PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders. |
| M27987 | CC214-2 | CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo. |
| M27795 | AZD3147 | AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K. |
| M27779 | PP30 | PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC50 of 80 nM. |
| M21167 | RMC-5552 | The selective mTORC1 complex inhibitor RMC-4529 is a bidentate inhibitor that has a rapamycin-derived, FKBP12-induced heterologous mTOR inhibitor covalently linked to an active-site (orthologous) inhibitor. |
| M14843 | PQR620 | PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
